Impact of IGF(CA)19 gene polymorphism on the metabolic response to GH therapy in adult GH-deficient patients

European Journal of Endocrinology

Volumn 170, Issue 2, 2014, Pages 273-281

  Giavoli, C ^a,b   Profka, E ^a,b   Sala, E ^a,b   Filopanti, M ^a,b   Barbieri, A M ^a,b   Bergamaschi, S ^a,b   Ferrante, E ^a,b   Arosio, M ^a,c   Ambrosi, B ^a   Lania, A G ^a,d   Spada, A ^a,b   Beck Peccoz, P ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^c San Giuseppe Hospital   (Italy)

^d HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RECOMBINANT GROWTH HORMONE; SOMATOMEDIN C; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY COMPOSITION; BODY FAT; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG DOSE TITRATION; FEMALE; GENETIC ASSOCIATION; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GROWTH HORMONE DEFICIENCY; HEMOGLOBIN BLOOD LEVEL; HETEROZYGOTE; HOMOZYGOTE; HORMONE SUBSTITUTION; HUMAN; IGF1 GENE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84893640838     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-13-0600     Document Type: Article

References (34)

1. De Boer H, Block GJ & van der Veen VA. Clinical aspects of growth hormone deficiency in adults. Endocrine Reviews 1995 16 63-86. (doi:10.1210/er.16.1.63)
2. Salomon F, Cuneo RC, Hesp R & Sonksen PH. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adult with growth hormone deficiency. New England Journal of Medicine 1989 321 1797-1803. (doi:10.1056/NEJM198912283212605)
3. Drake WM, Coyte D, Camacho-Hubner C, Jivanji NM, Kaltsas O, Wood DF, Trainer PJ, Grossman AB, Besser GM & Monson JP. Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults. Journal of Clinical Endocrinology and Metabolism 1998 83 3913-3919. (doi:10.1210/jc.83. 11.3913)
4. Motlich ME, Clemmons DR, Molozowski S, Merriam GR & Vance ML. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society Clinical Practice guideline. Journal of Clinical Endocrinology and Metabolism 2011 96 587-1609. (doi:10.1210/jc.2011-0179)
5. Johannsson G, Bjarnason R, Bramnert M, Carlsson LM, Degerbled M, Manhem P, Rosen T, Thorén M & Bengtsson BA. The individual responsiveness to growth hormone (GH) treatment in GH-deficient adults is dependent on the level of GH-binding protein body mass index, age and gender. Journal of Clinical Endocrinology and Metabolism 1996 81 1575-1581. (doi:10.1210/jc.81.4.1575)
6. Pantel J, Machinis K, Sobrier ML, Duquesnoy P, Goossens M & Amselem S. Species-specific alternative splicing mimicry at the growth hormone receptor locus revealed by the lineage of retroelements during primate evolution. Journal of Biological Chemistry 2000 275 18664-18669. (doi:10.1074/jbc.M001615200)
7. Dos Santos SC, Essioux L, Teinturier C, Tauber M, Goffin V & Bougneres P. A common polymorphism of the growth hormone receptor is associated with increased responsiveness to growth hormone. Nature Genetics 2004 36 720-724. (doi:10.1038/ng1379)
8. Wassenaar MJ, Dekkers OM, Pereira AM, Wit JM, Smit JW, Biermasz NR & Romijn JA. Impact of the exon 3-deleted growth hormone (GH) receptor polymorphism on baseline height and on the growth response to recombinant human GH therapy in GH-deficient (GHD) and non-GHD children with short stature: a systematic review and metaanalysis. Journal of Clinical Endocrinology and Metabolism 2009 94 3721-3730. (doi:10.1210/jc.2009-0425)
9. Giavoli C, Ferrante E, Profka E, Olgiati L, Bergamaschi S, Ronchi CL, Verrua E, Filopanti M, Passeri E, Montefusco L et al. Influence of the d3GH receptor polymorphism on the metabolic and biochemical phenotype of GH-deficient adults at baseline and during short-And long-term recombinant human GH replacement therapy. European Journal of Endocrinology 2010 163 361-368. (doi:10.1530/EJE-10-0317)
10. Vaessen N, Heutink P, Janssen JA, Witteman JC, Testers L, Hofman A, Lamberts SW, Oostra BA, Pols HA & van Duijn A. A polymorphism in the gene for IGF-I functional properties and risk for type 2 diabetes and myocardial infarction. Diabetes 2001 50 637-642. (doi:10.2337/diabetes.50.3.637)
11. Freylig TM, Hattersley AT, McCarthy A, Holly J, Mitchell SM, Gloyn AL, Owen K, Davies D, Davey Smith G & Ben-Shlomo Y. A putative functional polymorphism in the IGF-I gene. Association studies with type 2 diabetes, adult height, glucose tolerance, and fetal growth in U.K. populations. Diabetes 2002 51 2313-2316. (doi:10.2337/diabetes. 51.7.2313)
12. Allen NE, Davey GK, Key TJ, Zhang S & Narod SA. Serum insulin-like growth factor I (IGF-I) concentration in men is not associated with the cytosine-Adenosine repeat polymorphism in the IGF-I gene. Cancer Epidemiology, Biomarkers & Prevention 2002 11 319-320.
13. Rietveld I, Janssen JA, van Rossum EF, Houwing-Duistermaat JJ, Rivadeneira F, Hofman A, Pols HA, van Duijn CM & Lamberts SW. A polymorphic CA repeat in the IGF-I gene is associated with genderspecific differences in body height, but has no effect on the secular trend in body height. Clinical Endocrinology 2004 61 195-203. (doi:10.1111/j.1365-2265.2004. 02078.x)
14. Missmer SA, Haiman CA, Hunter DJ, Willett WC, Colditz GA, Speizer FE, Pollak MN & Hankinson SE. A sequence repeat in the insulin-like growth factor-1 gene and risk of breast cancer. International Journal of Cancer 2002 100 332-336. (doi:10.1002/ijc.10473)
15. Yu H, Li BD, Smith M, Shi R, Berkel HJ& Kato I. Polymorphic CA repeats in the IGF-I gene and breast cancer. Breast Cancer Research and Treatment 2002 70 117-122. (doi:10.1023/A:1012947027213)
16. Rosen CJ, Kurland ES, Vereault D, Adler RA, Rackoff PJ, Craeig WY, Witte S, Rogers J & Bilezikian JP. Association between serum insulin growth factor-I (IGF-I) and a simple sequence repeat in the IGF-I gene: implication for genetic studies of bone mineral density. Journal of Clinical Endocrinology and Metabolism 1998 83 2286-2290. (doi:10.1210/jc.83.7.2286)
17. Akin F, Turgut S, Cirak B & Kursunluoglu R. IGF(CA)19 and IGFBP-3-202A/C gene polymorphism in patients with acromegaly. Growth Hormone & IGF Research 2010 20 399-403. (doi:10.1016/j.ghir. 2010.09.001)
18. Meyer S, Schaefer S, Ivan D, Stolk L, Arp P, Uitterlinden GA, Nawroth PP, Plöckinger U, Stalla GK, Tuschy U et al. Growth hormone dose in growth hormone-deficient adults is not associated with IGF-I gene polymorphisms. Pharmacogenomics 2009 10 293-302. (doi:10.2217/14622416.10.2.293)
19. Ghigo E, Aimaretti G, Giannotti L, Bellone J, Arvat E & Camanni F. New approach to the diagnosis of growth hormone deficiency in adults. European Journal of Endocrinology 1996 134 352-356. (doi:10.1530/eje.0. 1340352)
20. Corneli G, Di Somma C, Baldelli R, Rovere S, Gasco V, Croce CG, Grottoli S, Maccario M, Colao A, Lombardi G et al. The cut-off limits of the GH response to GH-releasing hormone-Arginine test related to body mass index. European Journal of Endocrinology 2005 153 257-264. (doi:10.1530/eje.1.01967)
21. Porretti S, Giavoli C, Ronchi C, Lombardi G, Zaccaria M, Valle D, Arosio M & Beck-Peccoz P. Recombinant human GH therapy and thyroid function in a large group of adult GH-deficient patient: when does L-T(4) therapy become mandatory? Journal of Clinical Endocrinology and Metabolism 2002 87 2042-2045. (doi:10.1210/jc.87.5.2042)
22. Giavoli C, Libé R, Corbetta S, Ferrante E, Lania A, Arosio M, Spada A & Beck-Peccoz P. Effect of recombinant human growth hormone (GH) replacement on the hypothalamic-pituitary-Adrenal axis in adult GH-deficient patients. Journal of Clinical Endocrinology and Metabolism 2004 89 5397-5401. (doi:10.1210/jc.2004-1114)
23. Matthews DR, Hosker JP, Rudensky AS, Naylor BA, Tracher DF & Turner RC. Homeostasis model assessment: insulin resistance and b-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985 28 412-419. (doi:10.1007/BF00280883)
24. Friedwald WT, Levy RI & Friedrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical Chemistry 1972 18 499-502.
25. Segal KR, Van Loan M, Fitzgerald PI, Hodgdon JA & Van Itallie TB. Lean body mass estimation by bioelectrical impedance analysis: a four-site cross validation study. American Journal of Clinical Nutrition 1988 47 7-14.
26. Pichard C, Kyle UG, Bracco D, Slosman DO, Morabia A & Schutz Y. Reference values of fat-free and fat masses by bioelectrical impedance analysis in 3393 healthy subjects. Nutrition 2000 16 245-254. (doi:10.1016/S0899-9007(00) 00256-2)
27. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002 106 3143-3421.
28. Voorhoeve PG, van Rossum EF, Te Velde SJ, Koper JW, Kemper HC, Lamberts SW & de Waal HA. Association between an IGF-I gene polymorphism and body fatness: differences between generations. European Journal of Endocrinology 2006 154 379-388. (doi:10.1530/eje.1.02101)
29. West CA, Arnett TR & Farrow SM. Expression of IGF-I mRNA variants in rat bone. Bone 1996 19 41-46. (doi:10.1016/8756-3282(96)00105-6)
30. Naylor LH & Clark EM. d(TG)n:d(CA)n sequences upstream of the rat prolactin gene from Z-DNA and inhibit gene transcription. Nucleic Acids Research 1990 18 1595-1600. (doi:10.1093/nar/18.6.1595)
31. Arends N, Johnston L, Hoekken-Koelega A, Van Duijn C, De Ridder M, SavageM& Clark A. Polymorphism in the IGF-I gene: clinical relevance for short children born small for gestational age (SGA). Journal of Clinical Endocrinology and Metabolism 2002 87 2720-2724. (doi:10.1210/jc.87.6.2720)
32. Ester WA & Hoekken Koelega AC. Polymorphism in the IGFI and IGFI R genes and children born small for gestational age: results of large population studies. Best Practice & Research. Clinical Endocrinology & Metabolism 2008 22 415-431. (doi:10.1016/j.beem.2008.03.001)
33. Costalonga EF, Antonini SR, Guerra G Jr., Coletta RR, Franca MM, Braz AF, Mendonca BB, Arnhold IJ & Jorge AA. Growth hormone pharmacogenetics: the interactive effect of a microsatellite in the IGF-I promoter region with the GHR-exon 3 and K202 A/C IGFBP3 variants on treatments outcomes of children with severe GH deficiency. Pharmacogenomics Journal 2012 12 439-445. (doi:10.1038/tpj.2011.13)
34. Miletta MC, Scheidegger UA, Giordano M, Bozzola M, Pagani S, Bona G, DattaniM, Hindmarsh PC, Petkovic V, Oser-MeierMet al. Association of the (CA)n repeat polymorphism of insulin-like growth factor-I andK202 A/C IGF-binding protein-3 promoter polymorphismwith adult height in patients with severe growth hormone deficiency. Clinical Endocrinology 2012 76 683-690. (doi:10.1111/j.1365- 2265.2011.04267.x)